Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q9UIJ5 (
Rec
)
58,342
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Interleukin 35 (IL-35) is a heterodimeric cytokine involved in the development of atherosclerosis. The aim of the present study was to establish if the polymorphisms of
IL-12A
and
EBI3
genes that encode the IL-35 subunits are associated with the development of premature coronary artery disease (CAD) in Mexican individuals. The
IL-12A
and
EBI3
polymorphisms were determined in 1162 patients with premature CAD and 873 controls. Under different models, the
EBI3
rs428253 (OR = 0.831,
P
add
= 0.036; OR = 0.614,
P
rec
= 0.033; OR = 0.591,
P
cod2
= 0.027) and
IL-12A
rs2243115 (OR = 0.674,
P
add
= 0.010; OR = 0.676,
P
dom
= 0.014; OR = 0.698,
P
het
= 0.027; OR = 0.694,
P
cod1
= 0.024) polymorphisms were associated with decreased risk of developing premature CAD. Some polymorphisms were associated with clinical and metabolic parameters. Significant different levels of IL-35 were observed in
EBI3
rs4740 and rs4905 genotypes only in the group of healthy controls. In summary, our study suggests that the
EBI3
and
IL-12A
polymorphisms play an important role in decreasing the risk of developing premature CAD; it also demonstrates the relationship of the
EBI3
rs4740 and rs4905 genotypes with IL-35 levels in healthy individuals.
...
PMID:Interleukin 35 Polymorphisms Are Associated with Decreased Risk of Premature Coronary Artery Disease, Metabolic Parameters, and IL-35 Levels: The Genetics of Atherosclerotic Disease (GEA) Study. 2832 Nov 50
